search
Back to results

Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing (SES-DTA)

Primary Purpose

Anastomotic Leak, Rectal Cancer

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Cipro, metronidazole, neomycin combo
Serial Endoscopic Surveillance
Saline
Sponsored by
University of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Anastomotic Leak focused on measuring Rectal Cancer, low anterior resection, SES, SES-DTA, anastomotic leak, anastomotic healing, intestinal healing, anastomosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Diagnosis of rectal cancer
  • Scheduled to undergo a low anterior resection (with the planned anastomosis within 10cm of the anal verge) and a diverting ileostomy
  • 18 years of age or older
  • Able to provide informed consent

Exclusion Criteria

  • Prior medical history of or suspected diagnosis of inflammatory bowel disease or irritable bowel syndrome
  • Pregnant or breastfeeding
  • Allergy to lidocaine, ciprofloxacin, metronidazole or neomycin

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Cipro, metronidazole, neomycin combo

    Saline

    Arm Description

    As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.

    As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.

    Outcomes

    Primary Outcome Measures

    Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)

    Secondary Outcome Measures

    Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)
    Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)

    Full Information

    First Posted
    February 8, 2016
    Last Updated
    April 24, 2023
    Sponsor
    University of Chicago
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02682485
    Brief Title
    Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing
    Acronym
    SES-DTA
    Official Title
    A Multicenter, Phase II, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of Serial Endoscopic Surveillance (SES) and Direct Topical Antibiotics (DTA) to Define the Role of Microbes in Anastomotic Healing
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Lack of funding
    Study Start Date
    March 3, 2017 (Actual)
    Primary Completion Date
    March 3, 2017 (Actual)
    Study Completion Date
    March 3, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Chicago

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Rationale: The surgical complication of intestinal anastomotic leak remains a clear and present danger to patients despite advances in surgical technique and ever more powerful antibiotics. No surgeon is immune from this complication and leak rates have not changed in decades. The consequences of a leak (peritonitis, sepsis, death) can be so severe that in the case of rectal cancer, diverting ileostomies are routinely performed to divert the fecal stream away from the healing anastomosis. We have recently discovered that certain intestinal bacteria, with the capacity to express collagenase and cleave MMP9 (Matrix metallopeptidase 9) to its active collagen degrading form, play a key and causative role in anastomotic leak. These bacteria often escape elimination due to the failure of current antibiotic regimens and their delivery methods to remain functionally durable at anastomotic tissue sites. Purpose: This phase II clinical trial will track, in real time, the process of anastomotic healing and its associated microbiome by performing serial endoscopic surveillance (SES) following rectal cancer resection. By capturing anastomotic images and the associated microbial and inflammatory mediators from anastomotic fluids via SES performed at three time points following rectal cancer resection, we will correlate healing to microbial composition and inflammatory mediator status. Patients will be randomized and, at each time point, will receive lavage of their anastomosis with either saline or a triple antibiotic solution (ciprofloxacin, metronidazole, neomycin). An anastomotic healing score captured during SES will be compared between the two treatment arms and correlated to microbial and inflammatory mediator analyses of fluid samples to determine how intestinal microbes influence the process of anastomotic healing.
    Detailed Description
    OBJECTIVES Perform repeated postoperative endoscopy of anastomotic tissue sites in patients undergoing low anterior resection for rectal cancer with diverting ileostomy. Demonstrate that SES can reliably discriminate those anastomoses that progress along a continuum toward normal healing versus those that heal pathologically when images are evaluated by a jury blinded to treatment. Demonstrate that those anastomoses that are judged to progress pathologically harbor distinct microbial species and predictive inflammatory mediators. Demonstrate that when anastomotic tissues are lavaged with antibiotics directly via endoscopy (ciprofloxacin, metronidazole, neomycin), microbial pathogens that escape conventional antibiotics are eliminated and anastomotic healing progresses normally. Determine if the anastomotic healing score, microbial analyses, and/or inflammatory mediator analyses identify or predict symptomatic and clinically relevant anastomotic complications. STUDY This is a randomized, multicenter study. All patients undergo resection of rectal cancer with a low anterior resection with anastomoses within 10cm of the anal verge and diverting ileostomy. Patients will undergo three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28) (POD = post-operative day). During the SES procedure, the anastomosis will be lavaged with saline, the fluid will be collected by suction, images will be taken and then the anastomosis will be lavaged with either saline or an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin. Patients' clinical courses will be followed through chart review for 6 to 7 months following surgery. PROJECTED ACCRUAL A total of 200 patients (approximately 100 per treatment arm) will be accrued for this study within 4 years.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Anastomotic Leak, Rectal Cancer
    Keywords
    Rectal Cancer, low anterior resection, SES, SES-DTA, anastomotic leak, anastomotic healing, intestinal healing, anastomosis

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Cipro, metronidazole, neomycin combo
    Arm Type
    Experimental
    Arm Description
    As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
    Arm Title
    Saline
    Arm Type
    Placebo Comparator
    Arm Description
    As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
    Intervention Type
    Drug
    Intervention Name(s)
    Cipro, metronidazole, neomycin combo
    Other Intervention Name(s)
    Cipro/CiproXR/CiproIV; Flagyl/FlagylER/Metro; Neomycin
    Intervention Description
    During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
    Intervention Type
    Procedure
    Intervention Name(s)
    Serial Endoscopic Surveillance
    Other Intervention Name(s)
    SES
    Intervention Description
    Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
    Intervention Type
    Drug
    Intervention Name(s)
    Saline
    Other Intervention Name(s)
    0.9% saline solution
    Intervention Description
    During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
    Primary Outcome Measure Information:
    Title
    Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)
    Time Frame
    Post-operative day 12-28
    Secondary Outcome Measure Information:
    Title
    Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)
    Time Frame
    Post-operative day 0
    Title
    Anastomotic Healing Score (ordinal scale ranging from 0 to a maximum of 18)
    Time Frame
    Post-operative day 3-7

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria Diagnosis of rectal cancer Scheduled to undergo a low anterior resection (with the planned anastomosis within 10cm of the anal verge) and a diverting ileostomy 18 years of age or older Able to provide informed consent Exclusion Criteria Prior medical history of or suspected diagnosis of inflammatory bowel disease or irritable bowel syndrome Pregnant or breastfeeding Allergy to lidocaine, ciprofloxacin, metronidazole or neomycin
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    John C Alverdy, MD
    Organizational Affiliation
    University of Chicago
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    22952955
    Citation
    Olivas AD, Shogan BD, Valuckaite V, Zaborin A, Belogortseva N, Musch M, Meyer F, Trimble WL, An G, Gilbert J, Zaborina O, Alverdy JC. Intestinal tissues induce an SNP mutation in Pseudomonas aeruginosa that enhances its virulence: possible role in anastomotic leak. PLoS One. 2012;7(8):e44326. doi: 10.1371/journal.pone.0044326. Epub 2012 Aug 31.
    Results Reference
    background
    PubMed Identifier
    25947163
    Citation
    Shogan BD, Belogortseva N, Luong PM, Zaborin A, Lax S, Bethel C, Ward M, Muldoon JP, Singer M, An G, Umanskiy K, Konda V, Shakhsheer B, Luo J, Klabbers R, Hancock LE, Gilbert J, Zaborina O, Alverdy JC. Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak. Sci Transl Med. 2015 May 6;7(286):286ra68. doi: 10.1126/scitranslmed.3010658.
    Results Reference
    background

    Learn more about this trial

    Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing

    We'll reach out to this number within 24 hrs